SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."
Unlock the market timeline & signal feed
6 signals in the last 90 days.
The order this company entered each market — oldest to newest
Sr Manager, Medical Science Liaison - LOMBARDIA EST / TRIVENETO
Director, Medical Affairs
Sign up to see the full signal feed
How Alnylam Pharmaceuticals's international expansion compares to its competitors
Alnylam PharmaceuticalsYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Alnylam PharmaceuticalsYou | 5 | 2 | 0% | 6 | 33 |
Scientist, Process Sciences
View postingCambridge, MA · last wk.
Medical Science Liaison, Lead (Associate Director) - Italy
View postingGreater Rome Metropolitan Area · last wk.
Medical Science Liaison, Lead (Associate Director) - Italy
View postingMilan, Lombardy, Italy · last wk.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Alnylam Pharmaceuticals is facing FDA scrutiny over marketing claims related to its drug Amvuttra, raising regulatory compliance concerns.
Nasdaq announced six companies to be added to Nasdaq-100 Index, effective December 22, 2025, including Alnylam Pharmaceuticals and Ferrovial SE.
Nasdaq100 surged 1.58% as semiconductor stocks rebounded sharply. Micron led gains with 9.87% rise, while chip equipment makers KLAC, AMAT, ASML also jumped significantly.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Alnylam Pharmaceuticals's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
